Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma

Stopped early

Conditions studied: Diffuse Large B Cell Lymphoma

In brief

This research study is designed to test whether the results of a diffusion MRI scan performed after one cycle of chemotherapy for lymphoma can accurately predict the outcome of treatment for individual patients.

Key facts

Study ID: NCT00645359
Run by: University of Michigan Rogel Cancer Center
People needed: 9
Starts: 2006-11-01
Expected to finish: 2014-04-01
Last updated by the study team: 2017-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with a new diagnosis of CD20 Positive diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma, who will receive standard R/CHOP as first line chemotherapy will be included.
Patients must be age 18 or older.
No selection will be made on the basis of gender, race or ethnicity.

You may not qualify if…

Patients will be excluded if the diagnosis of diffuse large B cell lymphoma cannot be confirmed.
Patients receiving treatment other than R/CHOP or R/CHOP followed by radiotherapy or who have previously been treated for DLBCL will be excluded. - Patients with HIV infection will also be excluded. No selection will be made based on other medical problems or laboratory values, except as they affect the patient's eligibility to receive standard R/CHOP chemotherapy as determined by the treating physician.
Patients who have magnetic metal implants or fragments in their body that are incompatible with MRI will be excluded.

Where it is running

University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.